Author: admin

Ajayi AA, Sofowora GG, Ladipo GO. Explaining heart failure Hyper-mortality in sub saharan africa: global genomic and environmental contribution. J Natl Med Assoc. 2020;112(2):141–57.

PubMed 

Google Scholar 

Gillum RF. The burden of cardiovascular disease in sub-Saharan Africa and the black diaspora. J Racial Ethn Health Disparities. 2018;5(6):1155–8.

Article 
PubMed 

Google Scholar 

Alcaide-Aldeano A, Garay A, Alcoberro L, Jiménez-Marrero S, Yun S, Tajes M, et al. Iron deficiency: impact on functional capacity and quality of life in heart failure with preserved ejection fraction. J Clin Med. 2020;9(4):1199.

Article 
PubMed 
PubMed Central 

Google Scholar 

Johansson I, Joseph P, Balasubramanian K, McMurray JJV, Lund LH, Ezekowitz JA, et al. Health-related quality of life and mortality in heart failure: the global congestive heart failure study of 23 000 patients from 40 countries. Circulation. 2021;143(22):2129–42.

Akintunde AA, Akinlade OM, Egbewale BE, Opadijo OG. Iron deficiency anaemia in Nigerians with heart failure (IDAN-HF): therapeutic efficacy of iron replacement: an interventional study. Niger J Clin Pract. 2021;24(1):21–7.

Article 
PubMed 

Google Scholar 

Akintunde AA, Aworanti OW. Pattern of anaemia and its correlates in Nigerians with HF. Ann Ib Postgrad Med. 2020;18(1):51–9.

PubMed 
PubMed Central 

Google Scholar 

Loncar G, Obradovic D, Thiele H, von Haehling S, Lainscak M. Iron deficiency in Heart Failure. ESC Heart Fail. 2021;8(4):2368–79.

Article 
PubMed 
PubMed Central 

Google Scholar 

Dutt S, Hamza I, Bartnikas TB. Molecular mechanisms of iron and heme metabolism. Annu Rev Nutr. 2022;42:311–35.

Article 
PubMed 
PubMed Central 

Google Scholar 

Paolillo S, Scardovi AB, Campodonico J. Role of comorbidities in heart failure prognosis part I: anaemia, iron deficiency, diabetes, atrial fibrillation. Eur J Prev Cardiol. 2020;27(2suppl):27–34.

Article 
PubMed 
PubMed Central 

Google Scholar 

Martens P, Nijst P, Verbrugge FH, Smeets K, Dupont M, Mullens W. Impact of iron deficiency on exercise capacity and outcome in heart failure with reduced, mid-range and preserved ejection fraction. Acta Cardiol. 2018;73(2):115–23.

Article 
PubMed 

Google Scholar 

Chopra VK, Anker SD, Anaemia. Iron deficiency and heart failure in 2020: facts and numbers. ESC Heart Fail. 2020;7(5):2007–11.

Article 
PubMed 
PubMed Central 

Google Scholar 

Jacob C, Altevers J, Barck I, Hardt T, Braun S, Greiner W. Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia. ESC Heart Fail. 2019;6(4):840–55.

Article 
PubMed 
PubMed Central 

Google Scholar 

Lewis GD, Malhotra R, Hernandez AF, McNulty SE, Smith A, Felker GM, et al. Effect of oral iron repletion on exercise capacity in patients with heart failure with reduced ejection fraction and iron deficiency: the IRONOUT HF randomized clinical trial. JAMA. 2017;317:1958–66.

Article 
PubMed 
PubMed Central 

Google Scholar 

Beale A, Carballo D, Stirnemann J, Garin N, Agoritsas T, Serratrice J, et al. Iron deficiency in acute decompensated HF. J Clin Med. 2019;8:1569.

Article 
PubMed 
PubMed Central 

Google Scholar 

Beattie JM, Khatib R, Phillips CJ, Williams SG. Iron deficiency in 78,805 people admitted with HF across england: A retrospective cohort study. Open Heart. 2020;7:e001153.

Article 
PubMed 
PubMed Central 

Google Scholar 

Núñez J, Monmeneu JV, Mollar A, Núñez E, Bodí V, Miñana G, et al. Left ventricular ejection fraction recovery in patients with HF treated with intravenous iron: A pilot study. ESC Heart Fail. 2016;3:293–8.

Article 
PubMed 
PubMed Central 

Google Scholar 

Moliner PA, Jankowska E, Van Veldhuisen DJ, Farre N, Rozentryt P, Enjuanes C, et al. Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic HF. Int J Cardiol. 2017;243:360–6.

Article 
PubMed 

Google Scholar 

McDonagh T, MacDougall IC. Iron therapy for the treatment of iron deficiency in chronic HF: intravenous or oral? Eur J Heart Fail. 2015;17:248–62.

Article 
PubMed 

Google Scholar 

McDonagh T, Damy T, Doehner W, Lam CS, Sindone A, Van Der Meer P, et al. Screening, diagnosis and treatment of iron deficiency in chronic HF: putting the 2016 European society of cardiology HF guidelines into clinical practice. Eur J Heart Fail. 2018;20:1664–72.

Article 
PubMed 

Google Scholar 

Enjuanes C, Bruguera J, Grau M, Cladellas M, Gonzalez G, Meroño O, et al. Iron status in chronic HF: impact on symptoms, functional class and submaximal exercise capacity. Rev Esp Cardiol. 2016;69:247–55.

Article 
PubMed 

Google Scholar 

Comin-Colet J, Enjuanes C, Gonzalez G, Torrens A, Cladellas M, Meroño O, et al. Iron deficiency is a key determinant of health-related quality of life in patients with chronic HF regardless of anaemia status. Eur J Heart Fail. 2013;15:1164–72.

Article 
PubMed 
PubMed Central 

Google Scholar 

Naito Y, Tsujino T, Matsumoto M, Sakoda T, Ohyanagi M, Masuyama T. Adaptive response of the heart to long-term anemia induced by iron deficiency. Am J Physiol Heart Circ Physiol. 2009;296:H585-93.

Article 
PubMed 

Google Scholar 

Keller-Ross ML, Larson M, Johnson BD. Skeletal muscle fatigability in HF. Front Physiol. 2019;21:10:129.

Article 

Google Scholar 

Caminiti G, Sposato B, Volterrani M. The role of iron deficiency in HF. Eur Heart J Suppl. 2023;26(25Suppl C):C306-8.

Article 

Google Scholar 

Houstis NE, Eisman AS, Pappagianopoulos PP, Wooster L, Bailey CS, Wagner PD, et al. Exercise intolerance in HF with preserved ejection fraction: diagnosing and ranking its causes using personalized O2 pathway analysis. Circulation. 2017;137:148–61.

Article 
PubMed 
PubMed Central 

Google Scholar 

Wijk SS, Van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, et al. TIME-CHF Investigators. Circulating biomarkers of distinct pathophysiological pathways in HF with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17:1006–14.

Paulus WJ, Tschöpe C. A novel paradigm for HF with preserved ejection fraction. J Am Coll Cardiol. 2013;62:263–71.

Article 
PubMed 

Google Scholar 

Wijk SSV, Van Empel V, Davarzani N, Maeder MT, Handschin R, Pfisterer ME, ,;TIME-CHFInvestigators. Circulating biomarkers of distinct pathophysiological pathways in HF with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015;17:1006–14.

Article 

Google Scholar 

Hu D, Liu J, Zhang L, Bai X, Tian A, Huang X, et al. Health Status Predicts Short- and Long-Term Risk of Composite Clinical Outcomes in Acute HF. JACC Heart Fail. 2021;9(12):861–73.

Article 
PubMed 

Google Scholar 

Jankowska EA, Ponikowski P. Iron deficiency in HF: A Korea-Oriented review. Int J Heart Fail. 2023;5(4):173–83.

Article 
PubMed 
PubMed Central 

Google Scholar 

Rocha BML, Cunha GJL, Menezes Falcão LF. The burden of iron deficiency in HF: therapeutic approach. J Am Coll Cardiol. 2018;71(7):782–93.

Article 
PubMed 

Google Scholar 

Anker SD, Khan MS, Butler J, von Haehling S, Jankowska EA, Ponikowski P, Friede T. Effect of intravenous iron replacement on recurrent HF hospitalizations and cardiovascular mortality in patients with HF and iron deficiency: A bayesian meta-analysis. Eur J Heart Fail. 2023;25(7):1080–90.

Article 
PubMed 

Google Scholar 

Kalra PR, Cleland JGF, Petrie MC, Thomson EA, Kalra PA, Squire IB, IRONMAN Study Group, et al. Intravenous ferric derisomaltose in patients with HF and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial. Lancet. 2022;400(10369):2199–209. https://doi.org/10.1016/S0140-6736(22)02083-9.

Article 
PubMed 

Google Scholar 

Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, et al. FAIR-HF trial investigators. Ferric carboxymaltose in patients with HF and iron deficiency. N Engl J Med. 2009;361:2436–88.

Article 
PubMed 

Google Scholar 

Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, et al. Effects of Dapagliflozin on symptoms, function, and quality of life in patients with HF and reduced ejection fraction: results from the DAPA-HF. Trial Circulation. 2020;141:90–9.

Article 
PubMed 

Google Scholar 

Butler J, Anker SD, Filippatos G, Khan MS, Ferreira JP, Pocock SJ, et al. EMPEROR-reduced trial committees and investigators. Empagliflozin and health-related quality of life outcomes in patients with HF with reduced ejection fraction: the EMPEROR-Reduced trial. Eur Heart J. 2012;42:1203–12.

Article 

Google Scholar 

Forman DE, Fleg JL, Kitzman DW, Brawner CA, Swank AM, McKelvie RS, et al. 6-min walk test provides prognostic utility comparable to cardiopulmonary exercise testing in ambulatory outpatients with systolic HF. J Am Coll Cardiol. 2012;60:2653–61.

Article 
PubMed 
PubMed Central 

Google Scholar 

Shoemaker MJ, Curtis AB, Vangsnes E, Dickinson MG. Triangulating clinically meaningful change in the six-minute walk test in individuals with chronic HF: a systematic review. Cardiopulm Phys Ther J. 2012;23(3):5–15.

Article 
PubMed 
PubMed Central 

Google Scholar 

Opasich C, Pinna GD, Mazza A, Febo O, Riccardi R, Riccardi PG, et al. Six-minute walking performance in patients with moderate-to-severe HF; is it a useful indicator in clinical practice? Eur Heart J. 2001;22(6):488–96.

Article 
PubMed 

Google Scholar